4BASEBIO UK SOCIETAS (4BB.L)
4basebio plc engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. It provides AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. The company offers access to its targeted non-viral delivery platform, Hermes. It serves biotech, pharma, and contract development and manufacturing organization. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio plc in July 2021. 4basebio plc was founded in 2008 and is based in Cambridge, the United Kingdom.
Company Info
| ISIN | GB00BMCLYF79 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | £75.76M |
|---|---|
| EPS | -£0.42 |
| Revenue (TTM) | £268.00K |
| Gross Profit (TTM) | £269.00K |
| EBITDA (TTM) | -£5.33M |
| Year Range | £470.00 - £750.00 |
| Target Price | £1,200.00 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of £10,000 in 4BASEBIO UK SOCIETAS, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Return
4BASEBIO UK SOCIETAS had a return of -14.08% year-to-date (YTD) and 4.27% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| 1 month | -0.81% | 2.65% |
| 6 months | -10.29% | 10.31% |
| Year-To-Date | -14.08% | 11.39% |
| 1 year | 4.27% | 7.35% |
| 5 years (annualized) | 25.79% | 7.98% |
| 10 years (annualized) | N/A | N/A |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -2.72% | -8.39% | -2.29% | -11.72% | 1.77% | -2.61% | 9.82% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for 4BASEBIO UK SOCIETAS (4BB.L) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
|---|---|---|---|---|---|
4BB.L 4BASEBIO UK SOCIETAS | 0.11 | ||||
^GSPC S&P 500 | 0.74 |
Dividend History
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below shows the maximum drawdowns of the 4BASEBIO UK SOCIETAS. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.
The maximum drawdown since January 2010 for the 4BASEBIO UK SOCIETAS is 47.71%, recorded on Jul 13, 2022. The portfolio has not recovered from it yet.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -47.71% | Sep 30, 2021 | 196 | Jul 13, 2022 | — | — | — |
| -31.11% | Feb 22, 2021 | 15 | Mar 12, 2021 | 71 | Jun 25, 2021 | 86 |
| -9.72% | Sep 2, 2021 | 10 | Sep 15, 2021 | 10 | Sep 29, 2021 | 20 |
| -9.44% | Aug 10, 2021 | 6 | Aug 17, 2021 | 9 | Aug 31, 2021 | 15 |
| -5.38% | Jul 15, 2021 | 5 | Jul 21, 2021 | 7 | Jul 30, 2021 | 12 |
Volatility Chart
The current 4BASEBIO UK SOCIETAS volatility is 0.84%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.